Search Results

BML-190 50 mg  | 99.51%

TargetMol

BML-190 (Indomethacin morpholinylamide) is a specific CB2 receptor inverse agonist (Ki: 435 nM), with 50-fold selectivity over CB1 receptor.

More Information Supplier Page

BML-190 25 mg  | 99.51%

TargetMol

BML-190 (Indomethacin morpholinylamide) is a specific CB2 receptor inverse agonist (Ki: 435 nM), with 50-fold selectivity over CB1 receptor.

More Information Supplier Page

BML-190 100 mg  | 99.51%

TargetMol

BML-190 (Indomethacin morpholinylamide) is a specific CB2 receptor inverse agonist (Ki: 435 nM), with 50-fold selectivity over CB1 receptor.

More Information Supplier Page

AZD1981 5 mg  | 99.54%

TargetMol

AZD1981 is an effective and specific CRTh2 (DP2) receptor antagonist (IC50: 4 nM), showing >1000-fold selectivity over more than 340 other enzymes and receptors, including DP1. AZD1981 has been used in trials studying the treatment and basic science of Asthma, Postmenopausal, Pharmakokinetic, Asthma Patients, and Drug Interaction, among others.

More Information Supplier Page

AZD1981 50 mg  | 99.54%

TargetMol

AZD1981 is an effective and specific CRTh2 (DP2) receptor antagonist (IC50: 4 nM), showing >1000-fold selectivity over more than 340 other enzymes and receptors, including DP1. AZD1981 has been used in trials studying the treatment and basic science of Asthma, Postmenopausal, Pharmakokinetic, Asthma Patients, and Drug Interaction, among others.

More Information Supplier Page

AZD1981 100 mg  | 99.54%

TargetMol

AZD1981 is an effective and specific CRTh2 (DP2) receptor antagonist (IC50: 4 nM), showing >1000-fold selectivity over more than 340 other enzymes and receptors, including DP1. AZD1981 has been used in trials studying the treatment and basic science of Asthma, Postmenopausal, Pharmakokinetic, Asthma Patients, and Drug Interaction, among others.

More Information Supplier Page

(R)-(-)-Gossypol acetic acid 50 mg  | 96.73%

TargetMol

AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32 μM, 0.48 μM and 0.18 μM; does not inhibit BIR3 domain and BID. Phase 2.

More Information Supplier Page

BTZ043 Racemate 10 mg  | 98.47%

TargetMol

BTZ043 racemate is a decaprenylphosphoryl-β-D-ribose 2′-epimerase (DprE1) inhibitor, used as a new antimycobacterial agent.

More Information Supplier Page

BTZ043 Racemate 25 mg  | 98.47%

TargetMol

BTZ043 racemate is a decaprenylphosphoryl-β-D-ribose 2′-epimerase (DprE1) inhibitor, used as a new antimycobacterial agent.

More Information Supplier Page

BV6 5 mg  | Purity Not Available

TargetMol

BV6 is an antagonist of c-IAP1 and XIAP, members of the inhibitors of apoptosis (IAP) family.

More Information Supplier Page